NanoMaterials Technology Opens new US$1.5 Million Facility
Complete the form below to unlock access to ALL audio articles.
Singapore-based NanoMaterials Technology Pte Ltd has announced that it has opened its new US$1.54 million facility.
NMT was founded in 2000 and currently has 20 employees. NMT was included in Lux Research's ''Nanotechnology Report 2004'' as one of the top seven private nanotechnology companies in Asia.
It counts amongst its customers, 3M and Weyerhaeuser from the US, BASF from Germany and other multinational companies from Europe and Japan.
NMT recently concluded a funding round, bringing its total funding to date to US$7.7 million. This has allowed it to expand its facilities and capabilities to cater for further international growth.
A brand new laboratory, which includes a GMP facility and pharmaceutical and chemical laboratories, has been set up and NMT is also looking to further boost its R&D headcount to 30 persons.
To date, NMT has venture capital (VC) investors which include EDBV Management, Juniper Capital Ventures and 3V SourceOne, Japan Asia Investment Company (JAIC) and Korea Technology Investment Corp (KTIC).
NMT claims that its proprietary and patented High Gravity Controlled Precipitation (HGCP) technology platform is simple, easy to scale up and extremely cost effective compared to conventional production methods.
It is so versatile that it can be applied to various sectors like specialty chemicals, electronic materials and pharmaceuticals.
The technology for the production of nano-precipitated calcium carbonate (NPCC), the first nanomaterial developed by NMT, has already been out-licensed to several companies for industrial production.
NPCC has also been used in nano-composite development, where the addition of NPCC enhances mechanical properties.
The technology has been applied in the paper industry, where its use has been found to improve paper properties and lower paper production cost.
NMT has also developed electronic materials for use in multi-layer ceramic capacitors and these are currently being tested at some companies in the US and Japan.
In the area of pharmaceuticals, NMT has worked on several nano-drug compounds in solid oral form and for inhalation delivery and is actively targeting the pharmaceutical and drug delivery industry.
Its HGCP platform is designed to allow control over the specifications of drug particles. By reducing the active pharmaceutical ingredient particle size, drug efficacy and drug delivery performances has been shown to improve.
This will allow pharmaceutical and drug delivery companies to explore drug delivery systems which may not have been previously possible, opening a potential billion dollar market for NMT.
